MeaganAnneJacobyMD

Oncology • Saint Louis, MO

Hematologic Oncology

Instructor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Jacoby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jacoby's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-454-8304

Fax+1 314-454-5902

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
Washington University in St. Louis School of MedicineClass of 2005

Certifications & Licensure

MO State Medical License 2011 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2013 Nov 22
Completed
Phase 1
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance Start of enrollment: 2016 Jul 06
Active, not recruiting
Phase 2
A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes Start of enrollment: 2018 Jun 22
Completed
Phase 1
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Start of enrollment: 2018 Dec 14
Active, not recruiting
Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant Start of enrollment: 2022 May 12
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.
Meagan A Jacoby, Eric D Duncavage, Ajay Khanna, Gue Su Chang, Sridhar Nonavinkere Srivatsan
Leukemia. 2024-10-04
Identifying Molecular Markers of Relapse in Myelodysplastic Syndrome.
Meagan A. Jacoby, Matthew J. Walter
Oncology. 2018-12-17
47 citations
Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.
Meagan A. Jacoby, Eric J. Duncavage, Gue Su Chang, Christopher A. Miller, Jin Shao
JCI Insight. 2018-03-08

Journal Articles

Exome Analysis of Treatment‐Related AML After APL Suggests Secondary Evolution
John S Welch, Eric J Duncavage, Meagan A Jacoby, Peter Westervelt, Lukas D Wartman, British Journal of Haematology
Virescent Tongue
Rizwan Romee, Meagan Jacoby, Annals of Hematology

Abstracts/Posters

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
Meagan Jacoby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Meagan Jacoby, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

OncLive® to Host State of the Science Summit™ on Treatment of Hematologic MalignanciesNovember 5th, 2018
Post-Transplant Gene Mutations Predict Risk for MDS ProgressionNovember 1st, 2018
Genetic Testing Helps Predict Disease Recurrence in Myelodysplastic SyndromeSeptember 25th, 2018
Join now to see all